Clinical Trials Browser

Interventional × PEGPH20 × Gastrointestinal × Clear all

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT02921022 2025-11-26

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Phase NA Active not recruiting

Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT01959139 2024-02-09

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Phase 1/2 Completed

126 enrolled 19 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT01839487 2020-07-20

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Phase 2 Completed

279 enrolled 19 charts

Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

NCT02715804 2020-07-14

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Phase 3 Terminated

492 enrolled 16 charts

Gastrointestinal

Neoplasm Metastasis, Carcinoma, Pancreatic Ductal

NCT04058964 2020-03-13

Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02563548 2020-02-07

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Phase 1 Completed

56 enrolled 24 charts

Gastrointestinal

Stomach Neoplasms

NCT03267940 2020-02-07

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Phase 1 Terminated

85 enrolled 17 charts

Gastrointestinal

Cholangiocarcinoma

NCT04134468 2020-01-31

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT03481920 2019-08-22

A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer

Phase EARLY_PHASE1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT03634332 2019-05-07

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Phase 2 Unknown

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT02910882 2019-04-11

HALO-IST

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT01453153 2018-11-30

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Phase 1/2 Completed

28 enrolled 31 charts

Gastrointestinal

Neoplasms, Pancreatic Neoplasms